Skip to content

Newsroom

type
year
Illustration image.png

Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia

12/30/2019 Press release
Illustration image.png

33,944 Orion Corporation A shares converted into B shares

12/18/2019 Stock exchange release
Illustration image.png

Orion Corporation: Managers’ transactions – Sydäntutkimussäätiö sr.

12/13/2019 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

12/9/2019 Managers transactions
Illustration image.png

Orion Corporation: Managers’ transactions – Agendum Oy

12/9/2019 Managers transactions
Illustration image.png

Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND

12/9/2019 Press release
Illustration image.png

Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND

12/2/2019 Press release
Illustration image.png

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

11/28/2019 Flagging notifications
Illustration image.png

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

11/28/2019 Stock exchange release
Illustration image.png

192,172 Orion Corporation A shares converted into B shares

11/28/2019 Stock exchange release
Illustration image.png

Orion Research Foundation grants 902 000 euros for research in 2020

11/4/2019 Press release
Illustration image.png

125,000 Orion Corporation A shares converted into B shares

11/4/2019 Stock exchange release
Illustration image.png

Composition of the Nomination Committee of Orion Corporation

10/28/2019 Stock exchange release
Illustration image.png

Orion Group Interim Report 1–9/2019

10/23/2019 Stock exchange release
Illustration image.png

Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019

10/7/2019 Press release
Illustration image.png

135,000 Orion Corporation A shares converted into B shares

9/2/2019 Stock exchange release
Illustration image.png

Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone

8/7/2019 Press release
Illustration image.png

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)

7/31/2019 Press release